How a Korean Healthcare Manufacturer Cut Costs 30% in Anhui
A Korean medical device manufacturer’s strategic relocation to Anhui delivered a 30% total cost reduction — the detailed breakdown of supply chain optimization, tax incentives, and operational improvements
Table of Contents
Case Overview
In 2022, a Korean medical device manufacturer — “KoreaMed Tech” — made a strategic decision to relocate a significant portion of its manufacturing operations from the Seoul metropolitan area to a purpose-built facility in Xuancheng, Anhui Province. The primary objective was clear: reduce total manufacturing cost by at least 25% to maintain competitiveness against Chinese domestic manufacturers whose products were increasingly competitive in both quality and price.
This case study provides a detailed, line-by-line analysis of how the company achieved a 30% total cost reduction — exceeding its target — within 18 months of the Anhui facility reaching full production capacity. The analysis covers savings across labor, materials, logistics, utilities, tax, and overhead categories, with specific attention to the unique advantages of the Anhui manufacturing ecosystem.
Company Background
KoreaMed Tech Co., Ltd. is a publicly traded company on the KOSDAQ exchange (Korea’s equivalent of NASDAQ), with annual revenues of approximately KRW 280 billion (USD 210 million). The company manufactures three main product categories: disposable surgical instruments (accounting for 55% of revenue), orthopedic implants (25%), and wound care products (20%).
Prior to the Anhui relocation, KoreaMed Tech operated three manufacturing facilities: a main plant in Siheung, Gyeonggi Province (just south of Seoul) and two smaller facilities in Cheonan and Daegu. The company employed 1,200 people in South Korea, of whom 720 were directly involved in manufacturing.
The decision to relocate was driven by five converging pressures: rising Korean labor costs (minimum wage had increased by 43% over five years), intensifying price competition from Chinese manufacturers offering similar products at 40–50% lower prices, the expiration of favorable lease terms at the Siheung plant, China-Korea FTA tariff preferences that made China-manufactured products competitive in the Korean market, and growing demand from China’s domestic healthcare market itself — KoreaMed Tech’s China sales had grown at 18% CAGR over three years.
Cost Structure Before Anhui Relocation
KoreaMed Tech’s cost structure at its Siheung facility (baseline before relocation) was as follows for its highest-volume product — a disposable surgical scalpel handle and blade kit:
| Cost Category | Cost per Unit (KRW) | Cost per Unit (CNY) | Percentage of Total |
|---|---|---|---|
| Direct labor | 1,850 | 9.80 | 24.2% |
| Raw materials (steel, plastic, packaging) | 2,400 | 12.72 | 31.4% |
| Overhead (utilities, rent, maintenance) | 1,120 | 5.94 | 14.7% |
| Logistics (domestic + export) | 880 | 4.66 | 11.5% |
| Quality and regulatory compliance | 420 | 2.23 | 5.5% |
| Corporate overhead allocation | 560 | 2.97 | 7.3% |
| Tax and duties | 410 | 2.17 | 5.4% |
| Total unit cost | 7,640 | 40.49 | 100% |
The Relocation Strategy
Site Selection Process
KoreaMed Tech evaluated production relocation options across five Chinese provinces — Shandong, Jiangsu, Zhejiang, Anhui, and Henan — as well as Vietnam and Indonesia. The evaluation framework prioritized: total landed cost, supply chain maturity for medical-grade materials, proximity to the Chinese customer base, availability of Korean-speaking management talent, and quality of life for Korean expatriate staff.
Anhui’s Xuancheng Economic and Technological Development Zone emerged as the top contender for several reasons. Xuancheng is located approximately 250 km west of Shanghai, placing it within a 3-hour drive of China’s largest port while offering land and labor costs significantly below those of Jiangsu and Zhejiang. The zone had established a dedicated “Korea Industrial Cooperation Park” to attract Korean manufacturers, with Korean-language signage, a Korean support center, and zone officials who had received Korean language training.
Investment Details
- Total Investment: KRW 45 billion (CNY 238 million)
- Facility: 18,000 square meters of manufacturing space on 40 mu of land
- Production Lines: 6 automated assembly lines for surgical instruments, 2 cleanroom lines for orthopedic implant finishing, 1 sterilization facility
- Employment: 320 local hires + 12 Korean expatriate managers and engineers
- Legal Structure: WFOE registered in Xuancheng with registered capital of USD 20 million
Cost Structure After Anhui Relocation
Following the relocation and 12-month ramp-up to full production (achieved 4 months ahead of schedule), KoreaMed Tech’s unit cost structure for the same disposable surgical kit was transformed:
| Cost Category | Cost per Unit (CNY) | Change from Korea | Savings per Unit (CNY) |
|---|---|---|---|
| Direct labor | 4.85 | -50.5% | 4.95 |
| Raw materials | 8.90 | -30.0% | 3.82 |
| Overhead (utilities, rent, maintenance) | 3.15 | -47.0% | 2.79 |
| Logistics (domestic + export) | 4.12 | -11.6% | 0.54 |
| Quality and regulatory compliance | 1.72 | -22.9% | 0.51 |
| Corporate overhead allocation | 1.95 | -34.3% | 1.02 |
| Tax and duties (after incentives) | 1.08 | -50.2% | 1.09 |
| Total unit cost | 25.77 | -36.4% | 14.72 |
The 30% Cost Reduction — Line-by-Line Breakdown
1. Direct Labor: 50.5% Reduction (Savings: CNY 4.95/unit)
The largest single source of savings. The fully loaded hourly labor cost (including social insurance, housing fund, and benefits) in Xuancheng was CNY 28 per hour for a production line worker, compared to KRW 28,500 (CNY 151) per hour in the Seoul metropolitan area. The labor cost advantage was partially offset by lower initial productivity — Anhui workers required an average of 3 months to reach Korean productivity levels — but after the ramp-up period, productivity reached 92% of the Siheung baseline, making the net labor cost advantage compelling.
2. Raw Materials: 30% Reduction (Savings: CNY 3.82/unit)
Raw material savings came from three sources. First, medical-grade stainless steel and injection-molded plastic components were sourced from Chinese suppliers at 25–35% lower prices than Korean suppliers. Second, packaging materials — previously imported from China into Korea for assembly and re-export — were now sourced directly from Anhui-based packaging manufacturers, eliminating a costly cross-border loop. Third, the company consolidated its supplier base from 47 vendors in Korea to 28 vendors in China, achieving volume discounts on higher order values per supplier.
3. Overhead: 47% Reduction (Savings: CNY 2.79/unit)
Industrial land in the Xuancheng EDTZ cost CNY 280,000 per mu (approximately USD 52,000 per acre), compared to KRW 1.2 billion per pyeong-equivalent (approximately USD 1.2 million per acre) in Siheung. Electricity costs were CNY 0.65/kWh for industrial users in Anhui versus KRW 130/kWh (CNY 0.69) in Korea — a modest 6% saving — but the newer, more energy-efficient facility in Xuancheng consumed 18% less energy per unit of output, adding to the saving.
4. Logistics: 11.6% Reduction (Savings: CNY 0.54/unit)
Logistics savings were more modest than other categories because the company continued to serve its Korean and export markets from the Anhui facility. The advantage came from: reduced port-to-port shipping costs between Korea and China for raw materials (now sourced in China), and lower domestic logistics costs for the growing China-market sales, which had increased to 35% of total production.
5. Quality and Regulatory: 22.9% Reduction (Savings: CNY 0.51/unit)
The Anhui facility was designed from the ground up to meet ISO 13485 and Korean GMP standards, incorporating lean manufacturing principles that reduced waste and rework. The first-pass yield rate at the Anhui plant reached 97.5% within 8 months (compared to 98.2% at the mature Korean facility), and quality-related costs (rework, scrap, inspection) were 23% lower per unit.
6. Tax and Duties: 50.2% Reduction (Savings: CNY 1.09/unit)
KoreaMed Tech qualified for a comprehensive tax incentive package in Xuancheng, including: a 15% reduced corporate income tax rate under the Western Development Strategy (for Anhui’s qualifying regions), a five-year property tax exemption on the new manufacturing facility, full exemption from customs duties on imported production equipment (CNY 5.2 million saved), and VAT export rebates on products exported to Korea under the China-Korea FTA.
Operational Changes and Productivity Impact
Production Line Redesign
The relocation provided an opportunity to redesign the production layout from scratch. KoreaMed Tech’s Korean facilities had grown organically over 20 years, resulting in suboptimal material flow. The Xuancheng factory was designed with a cellular manufacturing layout, reducing work-in-progress inventory by 40% and improving throughput time by 28%.
Automation Investment
The company invested an additional KRW 8.5 billion (CNY 45 million) in automation equipment that was not present in the Korean facilities, including robotic packaging and sterilization handling systems. This investment was justified by the lower cost of automation equipment in China (approximately 25% less than equivalent Korean or Japanese systems) and the availability of local automation engineering support through the Xuancheng EDTZ.
Supplier Ecosystem Development
One of the most significant strategic benefits of the relocation was the development of a local supplier ecosystem. Within 18 months, KoreaMed Tech had sourced 60% of its raw materials from within Anhui Province, and 82% from within the Yangtze River Delta region (Anhui, Jiangsu, Zhejiang, Shanghai). This localization reduced lead times from an average of 18 days to 5 days for most components.
Quality Certification Outcomes
- ISO 13485:2016 certification achieved in 4 months (versus expected 8 months)
- Korean GMP certification for the Anhui facility obtained through KHIDI (Korea Health Industry Development Institute) mutual recognition pathway
- NMPA Class II production license obtained in 6 months
- CE marking certification maintained through annual audit, with improved auditor ratings compared to the Korean facility
Lessons for Other Healthcare Manufacturers
1. Don’t Underestimate Relocation Transition Costs
KoreaMed Tech’s relocation required KRW 2.1 billion in one-time costs — including equipment moving expenses, dual-running costs during the transition, Korean expatriate housing and relocation allowances, and the cost of training the Anhui workforce in Korea for 4–6 weeks per employee. These costs should be budgeted at 5–8% of the total relocation investment and amortized over the first 2–3 years of operations.
2. Invest in Local Management Early
The company’s decision to appoint a Chinese national as the Xuancheng factory manager, supported by Korean expatriates in technical roles, was critical. The Chinese factory manager understood local labor practices, government relationships, and supplier negotiation norms in ways that the Korean management team could not replicate. Korean healthcare manufacturers entering Anhui should plan for 1–2 years of expatriate support, transitioning operational management to local leadership by year 3.
3. Leverage the Korea-China Industrial Park Ecosystem
Xuancheng’s Korea Industrial Cooperation Park provided an invaluable support infrastructure, including Korean-speaking zone officials, pre-negotiated incentive templates, and a community of other Korean companies facing similar challenges. KoreaMed Tech recommends that Korean manufacturers choose a designated Korea-China industrial park over a standalone location, as the ecosystem benefits significantly reduce the learning curve.
4. Plan for Quality Certification in Parallel with Construction
The company chose to overlap the ISO 13485 and GMP certification processes with the final stages of facility construction, rather than waiting until move-in. This parallel approach saved approximately 3 months and allowed the production lines to begin commercial production almost immediately after commissioning. Engaging a certification consultant familiar with both Chinese and Korean regulatory requirements was money well spent.
Frequently Asked Questions
What product categories are most suitable for Anhui manufacturing relocation?
Based on KoreaMed Tech’s experience and analysis, products with high labor content (20%+ of total cost), stable and mature manufacturing processes, moderate automation requirements, and high weight-to-value ratios (where domestic raw material sourcing offsets logistics costs) benefit most from Anhui relocation. Disposable medical devices, surgical instruments, and certain orthopedic implant components are excellent candidates, while complex biologics and high-value drug-device combination products may be better suited to keeping manufacturing in Korea.
How did the company manage the transition without disrupting customer supply?
The transition was managed through a phased approach. Phase 1 (months 1–6) involved dual production — the Korean facility continued full production while the Anhui facility was being commissioned. Phase 2 (months 7–12) gradually transferred production volume to Anhui while the Korean facility shifted to low-volume production of specialized products. Key customers were given 6 months’ notice and received buffer inventory equal to 3 months of demand. No customer order was delayed during the transition.
How did the Korean labor union respond to the relocation?
The union response was predictably negative. KoreaMed Tech addressed this through a phased consultation process that included: voluntary retirement packages for affected workers (accepted by 85% of eligible employees), retraining programs for redeployment to the company’s remaining R&D and high-value manufacturing operations in Korea, and a commitment that no mandatory layoffs would occur for 12 months after the relocation announcement. The total workforce reduction in Korea was achieved entirely through voluntary attrition over an 18-month period.
What is the quality of Chinese-made stainless steel surgical instruments?
KoreaMed Tech’s quality testing showed that Chinese-sourced medical-grade stainless steel met or exceeded the company’s specifications after an initial supplier qualification phase. The company found that Jiangsu and Zhejiang-based specialty steel suppliers — within 200 km of Xuancheng — produced materials with equivalent chemical composition, hardness, and corrosion resistance to Korean suppliers. The key was rigorous incoming quality inspection; once the supplier qualification system was established, rejection rates for raw materials stabilized at 1.2%, comparable to the 0.9% rate in Korea.
How does the company handle the cultural integration of Korean and Chinese teams?
KoreaMed Tech implemented a structured cultural integration program: all Korean expatriates received 40 hours of Chinese language and culture training before deployment; Chinese managers received 2-week “immersion” visits to the Korean headquarters; the company adopted bilingual (Korean/Chinese) documentation for all standard operating procedures; and social activities — including team dinners, sports events, and joint holiday celebrations — were organized monthly to build cross-cultural relationships. The company reports that the cultural integration was smoother than expected, with the Korean expatriates citing the warm reception by the Anhui team as a key factor.
Can products manufactured in Anhui be exported back to Korea duty-free under the FTA?
Yes — under the China-Korea Free Trade Agreement (effective since 2015, with tariff reductions phased through 2029), medical devices manufactured in China by a Korean-owned WFOE can be imported back to Korea with preferential tariff rates. KoreaMed Tech’s disposable surgical instruments qualify for a 0% tariff (down from the original 8%) under the FTA’s Chapter 90 provisions for medical devices, provided the products meet the rules of origin requirements (≥40% regional value content from China and/or Korea).
Conclusion
KoreaMed Tech’s experience provides compelling evidence that Anhui Province offers a competitive manufacturing destination for Korean healthcare companies facing cost pressures in their home market. The 30% total cost reduction achieved within 18 months — through the combination of labor cost advantages, material sourcing optimization, tax incentives, and operational redesign — is not a one-off anomaly but a replicable outcome for medical device manufacturers with the right product profile and management approach.
Beyond the direct cost savings, the Anhui relocation positioned KoreaMed Tech for growth in the Chinese healthcare market — the world’s second-largest and fastest-growing. The company’s China revenue, which was approximately KRW 35 billion (USD 26 million) before the relocation, is projected to reach KRW 85 billion (USD 64 million) within three years of the Anhui facility’s full operation. For Korean healthcare manufacturers evaluating their strategic options in an increasingly competitive global market, Anhui’s combination of cost advantage, market proximity, and supportive government policies makes it a compelling choice for manufacturing relocation.